The Centre for Genomic Regulation (CRG) has recently signed a year-long collaboration agreement with Illumina, a leading developer and manufacturer of life sciences tools and integrated systems for large-scale analysis of genetic variation and function.
The agreement enables close collaboration between a research centre whose principal mission is the study of the genome and how it translates into characteristics that distinguish each individual, and an industry leader whose technology and products accelerate genetic analysis research and applications, paving the way for molecular medicine and ultimately transforming healthcare.
"This is the first step in a joint working relationship which I believe could be very fruitful, and which opens the door to more applied collaborations in the field of genomics, including the study of genetic diseases", says Luis Serrano, director of the CRG.
In addition, the agreement is aligned with the centre's strategic direction to foster collaboration between companies in the sector and the CRG. These kinds of alliances, and partnerships with hospitals, other research institutes and patient associations, are exactly what the CRG hopes to foster, as they are essential in attracting private funding and the development of a new economic model based on knowledge and innovation.
To this end, the CRG demonstrates its commitment to research and finding innovative solutions in difficult times, always striving to advance knowledge for the benefit of society, public health and economic prosperity.
NovaSeq, the new sequencer by Illumina, said to transform the field of genomics